[1]马咏梅.厄贝沙坦与黄葵胶囊对糖尿病肾病患者血清胱抑素C和β2-微球蛋白的影响[J].西部中医药,2017,30(11):106-109.
　MA Yongmei.Effects of Irbesartan and Ambrette Capsules on Serum Cystatin C and β2-microgloblin of the Patients with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2017,30(11):106-109.
点击复制

厄贝沙坦与黄葵胶囊对糖尿病肾病患者血清胱抑素C和β2-微球蛋白的影响()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年11期
页码:
106-109
栏目:
出版日期:
2017-11-15

文章信息/Info

Title:
Effects of Irbesartan and Ambrette Capsules on Serum Cystatin C and β2-microgloblin of the Patients with Diabetic Nephropathy
文章编号:
1004-6852(2017)11-0106-04
作者:
马咏梅
泰州市人民医院，江苏 泰州 225300
Author(s):
MA Yongmei
Taizhou Municipality People′s Hospital, Taizhou 225300, China
关键词:
糖尿病肾病; 血清胱抑素C; β2-微球蛋白; 厄贝沙坦; 黄葵胶囊
Keywords:
diabetic nephropathy;  serum cystatin C;  β2 -microgloblin;  irbesartan;  ambrette capsule
分类号:
R587.7
摘要:
目的：探讨厄贝沙坦联合黄葵胶囊对糖尿病肾病患者血清胱抑素C(CysC)和β2-微球蛋白的影响。方法：将糖尿病肾病患者120例随机分为试验组和对照组各60例。对照组行常规降血糖方案治疗，试验组患者在对照组治疗的基础上口服厄贝沙坦联合黄葵胶囊治疗，连续治疗2个月。对患者治疗前后血肌酐(Scr)、尿素氮(BUN)、24小时尿蛋白定量、CysC、β2-微球蛋白等指标进行观察。结果：试验组总有效率(86.7%)高于对照组(53.3%)，差异具有统计学意义( χ2=30.86，P=0.000)。治疗前2组患者Scr、BUN、尿酸等肾功能指标以及CysC、β2-微球蛋白等血清生化指标比较差异均无统计学意义(P＞0.05)；治疗后2组患者Scr、BUN、尿酸等肾功能指标均有不同程度降低，试验组降低程度优于对照组，差异有统计学意义(P＜0.05)。2组患者CysC、β2-微球蛋白等血清生化指标均有不同程度降低，且试验组低于对照组，差异具有统计学意义(P＜0.05)。结论：厄贝沙坦联合黄葵胶囊治疗糖尿病肾病疗效确切，能减少患者血清肌酐与尿蛋白浓度，能有效降低CysC和β2-微球蛋白浓度，起到保护肾脏微血管作用。
Abstract:
Objective: To explore the influence of irbesartan combined with ambrette capsule on cystatin C and β2-microgloblin in the treatment of diabetic nephropathy (DN). Methods: A total of 120 DN patients were randomly divided into the control group and the study group, the control group received conventional hypoglycemic threapy，the study group took irbesartan combined with ambrette capsule on the foundation of the treatment the control group accepted. Both groups were treated for two months consecutively. The indexes of Scr, BUN, 24 h uPro, cystatin C and β2 -microgloblin in both groups were analyzed before and after treating. Results: Total effective rate of the study group was 86.7%, higher than 53.3% of the control group, and the difference had statistical meaning ( χ2=30.86, P=0.000). There was no significant difference in the comparisons of Scr, BUN, 24 h uPro, uric acid, cystatin C and β2 -microgloblin between the two groups before treating (P＞0.05); after the treatment, renal indexes including Scr, BUN, UA and others decreased to different degrees in both groups, and th study group was superior to the control group, and the difference had statistical meaning (P＜0.05). The biochemical indexes of cystatin C and β2 -microgloblin in both groups lowered to different extents, and the study group was lower than the control group and the difference had statistical meaning (P＜0.05). Conclusion: Irbesartan combined with ambrette capsule could gain definite effects in the treatment of DN, it could reduce Scr and urinary protein concentrations of the patients, effectively decrease the concentrations of cystatin C and β2-microgloblin, and it could take effects of protecting renal micrangium.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(11):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(11):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):96.

备注/Memo

备注/Memo:
收稿日期：2017-02-27 作者简介：马咏梅(1970—)，女，副主任医师。研究方向：内分泌系统疾病的诊治。
更新日期/Last Update: 2017-11-15